研究单位：[1]BeiGene[2]Blacktown Cancer and Haematology Centre,Blacktown,New South Wales,Australia,2148[3]Campbelltown Hospital,Campbelltown,New South Wales,Australia,2560[4]St George Hospital,Kogarah,New South Wales,Australia,2217[5]The Tweed Hospital,Tweed Heads,New South Wales,Australia[6]Cairns and Hinterland Hospital and Health Service,Cairns,Queensland,Australia,4870[7]Gallipoli Medical Research Foundation (Greenslopes Private Hospital),Greenslopes,Queensland,Australia,4120[8]Cancer Research South Australia,Adelaide,South Australia,Australia,5000[9]Monash Health,Clayton,Victoria,Australia[10]St Vincent's Hospital Melbourne,East Melbourne,Victoria,Australia,3002[11]Northern Hospital,Epping,Victoria,Australia,3076[12]Sunshine Hospital, Western Health,Saint Albans,Victoria,Australia,3021[13]Pindara Private Hospital,Benowa,Australia,4217[14]Anhui Cancer Hospital aka West Branch of Anhui Province Hospital,Hefei,Anhui,China,230001[15]Beijing Cancer Center,Beijing,Beijing,China,100142[16]Peking Union Medical College Hospital - Oncology,Beijing,Beijing,China,100730[17]Beijing Cancer Hospital,Beijing,Beijing,China[18]Cancer Hospital Chinese Academy of Medical Science,Beijing,Beijing,China[19]Xinqiao Hospital Affiliated to The Army Medical University,Chongqing,Chongqing,China,400030[20]Daping Hospital, Third Military Medical University,Chongqing,Chongqing,China,400042[21]Fujian Provincial Cancer Hospital,Fuzhou,Fujian,China,350014[22]First Affiliated Hospital of Xiamen University,Xiamen,Fujian,China,361003[23]First Hospital of Lanzhou University,Lanzhou,Gansu,China,730000[24]Cancer Center of Guangzhou Medical University,Guangzhou,Guangdong,China,510059[25]Guangdong Provincial People's Hospital,Guangzhou,Guangdong,China,510080[26]Nanfang Hospital of Southern Medical University,Guangzhou,Guangdong,China,510515[27]Cancer Hospital of Shantou University Medical College - Oncology,Shantou,Guangdong,China,515031[28]Affiliated Tumor Hospital of Guangxi Medical University,Nanning,Guangxi,China,530021[29]The People's Hospital of Guangxi Zhuang Autonomous Region,Nanning,Guangxi,China,530021[30]Harbin Medical University Cancer Hospital,Harbin,Heilongjiang,China,150081[31]Henan Cancer Hospital,Zhengzhou,Henan,China,450008[32]The First Affiliated Hospital of Zhengzhou University,Zhengzhou,Henan,China,450052[33]Union Hospital of Tongji Medical College, Huazhong University of Science and Technology,Wuhan,Hubei,China,430022[34]Tongji Hospital of Tongji Medical College Huazhong University of Science Technology,Wuhan,Hubei,China,430030[35]Hubei cancer hospital,Wuhan,Hubei,China,430070[36]The Second Xiangya Hospital central South University,Changsha,Hunan,China,410011[37]The First People's Hospital of Chenzhou,Chenzhou,Hunan,China,430407[38]The Second Hospital, University of South China,Hengyang,Hunan,China,430407[39]Nanjing First Hospital,Nanjing,Jiangsu,China,210009[40]Zhongda Hospital Southeast University,Nanjing,Jiangsu,China,210009[41]The Second Affiliated Hospital of Soochow University,Suzhou,Jiangsu,China,215000[42]The First Affiliated Hospital of Soochow University,Suzhou,Jiangsu,China[43]The Affiliated Hospital of Xuzhou Medical University,Xuzhou,Jiangsu,China,221000[44]The Second Affiliated Hospital of Nanchang University,Jiangxi,Jiangxi,China,330006[45]The First affiliated hospital of Nanchang University,Nanchang,Jiangxi,China,330006[46]The First Hospital of Jilin University,Changchun,Jilin,China,130021[47]The First Hospital of Dalian Medical University,Dalian,Liaoning,China,116044[48]Liaoning Cancer Hospital & Institute - Medical Oncology - Oncology,Shenyang,Liaoning,China,110017[49]General Hospital of Ningxia Medical University,Yinchuan,Ningxia,China[50]Jinan Central Hospital,Jinan,Shandong,China,250013[51]Shandong Cancer Hospital,Jinan,Shandong,China,250117[52]Affiliated hospital of Qingdao University,Qingdao,Shandong,China,266003[53]Ruijin Hospital, Shanghai Jiaotong Uni. School of Med.,Shanghai,Shanghai,
研究目的：
The purpose of this study is to evaluate the efficacy and safety of tislelizumab in combination with sitravatinib compared with docetaxel in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have disease progression following platinum-based chemotherapy and anti-programmed cell death protein-1 (PD-1)/programmed cell death ligand-1 (PD-L1) antibody, with the anti-PD-(L)1 antibody administered in combination with or sequentially before or after the platinum-based chemotherapy.
